FDA OKs First-in-Class Sotatercept for PAH

The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, to increase exercise capacity, improve WHO functional class, and reduce the risk for clinical worsening events. Sotatercept, which had breakthrough therapy designation…
Read More